Clinical Research Program Archives - Page 2 of 19

A multiple myeloma physician talking with a nurse in the clinic.

March is Multiple Myeloma Awareness Month, an opportunity to shed light on a disease that accounts for approximately 10% of all blood cancers. Treatment options for multiple myeloma have expanded in recent years, leading to better patient outcomes and longer survival rates.

Human colon cancer cells with the cell nuclei stained red and the protein E-cadherin stained green. E-cadherin is a cell adhesion molecule and its loss signals a process known as the epithelial-mesenchymal transition in which cells acquire the ability to migrate and become invasive.

UNC Lineberger researchers have demonstrated that combining two immunotherapy drugs with a targeted therapy drug proved effective in treating the most common form of metastatic colorectal cancer.

UNC Lineberger has opened a two-arm clinical trial to determine the optimal combination treatment for patients with advanced unresectable or metastatic basal-like subtype pancreatic ductal adenocarcinoma.

Tag: Clinical Research Program

Improved multiple myeloma therapies help patients live longer, better lives

Oncology Nurse Advisor: Adjuvant Nivolumab Prolongs DFS, OS in MIBC

Immunotherapy and targeted therapy combination proves effective against metastatic colorectal cancer

CancerNetwork: Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Medscape: Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis

MedPage Today: Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer

CURE: Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC

Study now recruiting patients to treat PANcreatic adenocarcinoma with Gemcitabine, Erlotinib, and nAb-paclitaxel (PANGEA)

CancerNetwork: Adjuvant Nivolumab Shows Sustained DFS Benefit in High-Risk Bladder Cancer

OncLive: Updated CheckMate-274 Data Further Support Adjuvant Nivolumab as SOC for High-Risk MIUC